<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Neurodegener</journal-id><journal-title-group><journal-title>Molecular Neurodegeneration</journal-title></journal-title-group><issn pub-type="epub">1750-1326</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1750-1326-5-11</article-id><article-id pub-id-type="pmid">20302621</article-id><article-id pub-id-type="doi">10.1186/1750-1326-5-11</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short report</subject></subj-group></article-categories><title-group><article-title>Ubiquitin carboxy-terminal hydrolase L1 <italic>(UCHL1) </italic>S18Y polymorphism in Alzheimer's disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Zetterberg</surname><given-names>Madeleine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>madeleine.zetterberg@gu.se</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Sj&#x000f6;lander</surname><given-names>Annica</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>annica.sjolander@neuro.gu.se</email></contrib><contrib contrib-type="author" id="A3"><name><surname>von Otter</surname><given-names>Malin</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>malin.vonotter@gu.se</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Palm&#x000e9;r</surname><given-names>Mona Seibt</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>mona.palmer@vgregion.se</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Landgren</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>sara.landgren@pharm.gu.se</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Minthon</surname><given-names>Lennart</given-names></name><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>lennart.minthon@skane.se</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Wallin</surname><given-names>Anders</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>anders.wallin@neuro.gu.se</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Andreasen</surname><given-names>Niels</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>niels.andreasen@ki.se</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kaj.blennow@neuro.gu.se</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>henrik.zetterberg@clinchem.gu.se</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation, Section of Ophthalmology, The Sahlgrenska Academy at the University of Gothenburg, M&#x000f6;lndal, Sweden</aff><aff id="I2"><label>2</label>Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, M&#x000f6;lndal, Sweden</aff><aff id="I3"><label>3</label>Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, The Sahlgrenska Academy at the University of Gothenburg, G&#x000f6;teborg, Sweden</aff><aff id="I4"><label>4</label>Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, G&#x000f6;teborg, Sweden</aff><aff id="I5"><label>5</label>Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden</aff><aff id="I6"><label>6</label>Neuropsychiatric Clinic, Malm&#x000f6; University Hospital, Malm&#x000f6;, Sweden</aff><aff id="I7"><label>7</label>Memory clinic, M51, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Stockholm, Sweden</aff><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2010</year></pub-date><volume>5</volume><fpage>11</fpage><lpage>11</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2009</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2010 Zetterberg et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder>Zetterberg et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.molecularneurodegeneration.com/content/5/1/11"/><abstract><p>Alzheimer's disease (AD) is characterized by protein aggregates, <italic>i.e</italic>. senile plaques and neurofibrillary tangles. The ubiquitin-proteasome system has been proposed a role in proteolytic removal of these protein aggregates. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a de-ubiquitinating enzyme with important functions in recycling of ubiquitin. The S18Y polymorphism of the <italic>UCHL1 </italic>gene confers protection against Parkinson's disease. In this study, the genotype and allele frequencies of the <italic>UCHL1 </italic>S18Y polymorphism were investigated in 452 AD patients and 234 control subjects, recruited from four memory clinics in Sweden. Using a binary logistic regression model including <italic>UCHL1 </italic>allele A and <italic>APOE </italic>&#x003b5;4 allele positivity, age and sex as covariates with AD diagnosis as dependent variable, an adjusted OR of 0.82 ([95% CI 0.55-1.24], <italic>P </italic>= 0.35) was obtained for a positive <italic>UCHL1 </italic>allele A carrier status. The present study thus do not support a protective effect of the <italic>UCHL1 </italic>S18Y polymorphism against AD.</p></abstract></article-meta></front><body><sec><title>Findings</title><p>Aggregation of aberrant proteins is a hallmark of several neurodegenerative diseases, including Alzheimer's (AD), Huntington's (HD) and Parkinson's (PD) diseases. In this context, the ubiquitin-proteasome system (UPS) has been ascribed a central role in preventing the formation of pathological protein aggregates by proteolytic removal of defect proteins [<xref ref-type="bibr" rid="B1">1</xref>]. Proteins destined for degradation by the UPS are labelled with a 76-amino acid peptide, ubiquitin, through a series of conjugation steps by the E1, E2 and E3 enzymes respectively. There are also two classes of de-ubiquitinating enzymes; the ubiquitin-specific processing proteases (UBPC) and the ubiquitin carboxy-terminal hydrolase family (UHC). For recent reviews on the UPS, see [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is an isoform of the UHC group, expressed mainly in neurons and testis/ovary. However, UCHL1 has also been found in cells of the human diffuse neuroendocrine system and is expressed is several forms of cancer [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. UCHL1 has an important role in recycling of ubiquitin through hydrolysis of peptide-ubiquitin bonds and processing of ubiquitin precursors, but it also possesses ubiquitin ligase activity [<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, it has been shown that UCHL1 associates with monoubiquitin and elongates its half-life, thus ensuring stability of ubiquitin within neurons [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Several genetic variants of the <italic>UCHL1 </italic>gene have been described; both those leading to gain-of-function and those resulting in loss-of-function. The I93 M mutant results in 50% reduced activity [<xref ref-type="bibr" rid="B9">9</xref>], whereas the S18Y variant exhibits increased hydrolytic activity [<xref ref-type="bibr" rid="B10">10</xref>]. Other studies showed comparable hydrolase activity of the <italic>UCHL1 </italic>S18Y variant when compared to the wild type enzyme, but a reduction in ligase activity [<xref ref-type="bibr" rid="B11">11</xref>]. It has also been demonstrated that the <italic>UCHL1 </italic>S18Y polymorphism has a specific ability to act as a potent antioxidant in neuronal cell culture systems [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>A number of reports have demonstrated a protective effect of the S18Y polymorphism against sporadic PD in different populations [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>], although conflicting data exist [<xref ref-type="bibr" rid="B17">17</xref>]. As for AD, data on <italic>UCHL1 </italic>genotype frequencies and its effect on risk of AD is scarce and conflicting [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. The purpose of this study was to investigate the <italic>UCHL1 </italic>S18Y polymorphism in AD patients and controls in the Swedish population. Given that we, for subsets of the participants, have previously collected data on levels of CSF biochemical markers and neuropathological scores for AD, associations between the <italic>UCHL1 </italic>S18Y polymorphism and these variables could be investigated in addition to the genetic risk analysis.</p><p>The study population consisted of 452 patients with AD and 234 subjects without dementia, all of Swedish nationality. The AD patients and control subjects were recruited and diagnosed from four memory clinics in Sweden; Malm&#x000f6; (371 patients, 48 controls), Huddinge (52 patients, 70 controls), G&#x000f6;teborg/M&#x000f6;lndal (29 patients, 95 controls) and Link&#x000f6;ping (21 controls). The patients were invited to participate at their first visit to the respective clinic, where they also gave their informed consent. The control subjects were recruited by advertisement in the local newspapers or at senior citizen organization meetings. A few of these controls were spouses or unrelated friends of the patients. The study was approved by the local Ethical Commissions at the respective academic center and the tenets of the Declaration of Helsinki were followed. Parts of the AD and the control groups in this work have also been included in previous studies on other polymorphisms [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>].</p><p>All AD patients underwent clinical examination, neuropsychological evaluations including Mini-Mental State Examinaton (MMSE), computed tomography (CT) or magnetic resonance imaging (MRI) of the brain and routine blood analyses. The healthy elderly controls were classified as non-demented on the basis of a structured interview performed by a research nurse that included information on health history, lifestyle-related variables and psychosocial situation. Only controls with an MMSE score of at least 26 were included in the study. In addition, 65 years was set as the youngest age of controls for participation in the study.</p><p>Patients were clinically diagnosed with probable late-onset AD according to the NINCDS-ADRDA criteria [<xref ref-type="bibr" rid="B22">22</xref>] by a dementia investigation team that included specialists in geriatric medicine and psychiatry. To avoid inclusion of cases with familial Alzheimer's disease (FAD) only patients 60 years of age or older were included in the study. In addition, all patients were questioned about their family history regarding AD and those with suspect heredity were excluded. Individuals with significant psychiatric or somatic diseases other than AD were excluded. Data on CSF biomarkers, including the concentrations of total-tau (T-tau), phospho-tau<sub>181 </sub>(P-tau<sub>181</sub>) and A&#x003b2;<sub>1-42 </sub>was available for 260 of the AD patients and 117 of the controls. Neuropathological diagnosis and scores based on senile plaques and neurofibrillary tangles were available for 65 of the AD patients and 80 of the controls. Genomic DNA was extracted from whole blood samples and brain tissue using standard methods. <italic>APOE </italic>(gene map locus 19q13.2) genotyping had previously been performed by minisequencing, as described in detail [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>The <italic>UCHL1 </italic>(gene map locus 4p14; [Entrez gene ID: 7345]) S18Y, 54C&#x0003e;A polymorphism (rs5030732) was analyzed using the Dynamic Allele Specific Amplification (DASH) tehnology as described earlier [<xref ref-type="bibr" rid="B24">24</xref>]. The PCR were carried out with HotStarTaq DNA Polymerase<sup>&#x000ae; </sup>(QIAGEN, Hilden, Germany) in a final volume of 25 &#x003bc;l, containing 5-20 ng of template DNA. Optimal conditions were: 1 mM MgCl<sub>2</sub>, 0.2 mM dNTPs, 0.02 U Taq polymerase, 0.16 pmol/&#x003bc;l of the forward biotinylated primer (5'Biotin-GCCGCCTTGTCTCCTCTCAGCAG3') and 0.78 pmol/&#x003bc;l of the reverse primer (5'GTCACTGGCCTGCGACCCC3'), (Invitrogen, Paisley, UK) in 1 &#x000d7; PCR buffer (Roche, Mannheim, Germany). The cycling profile was: 15 min at 95&#x000b0;C, then 39 cycles: 30 sec at 95&#x000b0;C, 45 sec at 60&#x000b0;C, 45 sec at 72&#x000b0;C and finally 10 min at 72&#x000b0;C. To identify <italic>UCHL1 </italic>alleles the probe 5'GACAGAAACGCACTTGT-Rox3' (MWG Biotech, London, United Kingdom) was used. The accuracy of the DASH method was verified by DNA sequencing of 15 individuals representing the different <italic>UCHL1 </italic>genotypes (five of each genotype).</p><p>Primary analyses compared differences between the AD patients and control subjects regarding age, sex, MMSE score, biochemical markers, neuropathological scores, genotype and allele frequencies using Fisher's exact &#x003c7;<sup>2 </sup>test, <italic>t</italic>-test and Mann-Whitney U test. Secondary analysis of <italic>UCHL1 </italic>allele A-carrier status was performed with a binary logistic regression model with diagnosis (AD versus control) as dependent variable and allele positivity, age, sex and <italic>APOE </italic>&#x003b5;4 allele status as independent variables. Significance was set at <italic>P </italic>&#x0003c; 0.05. SPSS 16.0 (SPSS Inc, Chicago, Il) was used as statistic software.</p><p>In the AD group the mean age was 76.2 (SD 6.4) years (range 60-102 years) and 299 (66.2%) were women. In the control group the mean age was 75.9 (SD 7.1) years (range 65-94 years) and 127 (58.8%) were women. A summary of demographic and clinical characteristics is presented in table <xref ref-type="table" rid="T1">1</xref>, including MMSE score, CSF biomarkers, neuropathological score and <italic>APOE </italic>&#x003b5;4 allele-carrier status.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic, clinical and genetic characteristics of patients with AD and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristic</th><th align="left">AD patients (n = 452)</th><th align="left">Controls (n = 234)</th><th align="center"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left">Sex, f/m (%)</td><td align="left">299/153 (66.2/33.8)</td><td align="left">127/89 (58.8/41.2)</td><td align="center">0.071*</td></tr><tr><td/><td align="left">n = 452</td><td align="left">n = 216</td><td/></tr><tr><td align="left">Age, years,</td><td align="left">76.2 &#x000b1; 6.4 (60-102)</td><td align="left">75.9 &#x000b1; 7.1 (65-94)</td><td align="center">0.215<sup>&#x02020;</sup></td></tr><tr><td align="left">Mean &#x000b1; SD (range)</td><td align="left">n = 341</td><td align="left">n = 216</td><td/></tr><tr><td align="left">MMSE score, Median (25<sup>th </sup>-- 75<sup>th </sup>percentiles)</td><td align="left">22 (19-25) n = 367</td><td align="left">29 (29-30) n = 113</td><td align="center">&#x0003c;0.001<sup>&#x02021;</sup></td></tr><tr><td align="left">T-tau (pg/ml), Mean &#x000b1; SD</td><td align="left">621 &#x000b1; 319 n = 260</td><td align="left">376 &#x000b1; 162 n = 117</td><td align="center">&#x0003c;0.001<sup>&#x02020;</sup></td></tr><tr><td align="left">P-tau<sub>181 </sub>(pg/ml), Mean &#x000b1; SD</td><td align="left">76.9 &#x000b1; 31.2 n = 260</td><td align="left">63.3 &#x000b1; 19.9 n = 91</td><td align="center">&#x0003c;0.001<sup>&#x02020;</sup></td></tr><tr><td align="left">A&#x003b2;<sub>1-42 </sub>(pg/ml), Mean &#x000b1; SD</td><td align="left">409 &#x000b1; 100 n = 260</td><td align="left">720 &#x000b1; 200 n = 117</td><td align="center">&#x0003c;0.001<sup>&#x02020;</sup></td></tr><tr><td align="left">SPs and NFTs score, Median (25<sup>th </sup>-- 75<sup>th</sup>percentiles)</td><td align="left">7 (6-8.5) n = 65</td><td align="left">1 (0-3) n = 80</td><td align="center">&#x0003c;0.001<sup>&#x02020;</sup></td></tr><tr><td align="left"><italic>APOE &#x003b5;4 </italic>allele-carriers n (%)<break/>number of <italic>&#x003b5;4 </italic>alleles:</td><td/><td/><td/></tr><tr><td align="left">&#x02003;0</td><td align="left">128 (28.3)</td><td align="left">156 (72.2)</td><td align="center">&#x0003c;0.001*</td></tr><tr><td align="left">&#x02003;1</td><td align="left">238 (52.7)</td><td align="left">55 (25.5)</td><td align="center">&#x0003c;0.001*</td></tr><tr><td align="left">&#x02003;2</td><td align="left">86 (19.0)</td><td align="left">5 (2.3)</td><td align="center">&#x0003c;0.001*</td></tr><tr><td/><td align="left">n = 452</td><td align="left">n = 216</td><td/></tr></tbody></table><table-wrap-foot><p>*Fisher's Exact Test, <sup>&#x02020;</sup>Mann-Whitney U-test. AD = Alzheimer's disease, SD = Standard Deviation, MMSE = Mini Mental State Examination, A&#x003b2; = &#x003b2;-amyloid, SPs = senile plaques, NFTs = neurofibrillary tangles</p></table-wrap-foot></table-wrap><p>Genotype and allele frequencies for the <italic>UCHL1 </italic>S18Y polymorphism are shown in table <xref ref-type="table" rid="T2">2</xref>. There was a significant overrepresentation of the heterozygous genotype (AC) in the control group (p = 0.03). There were no significant differences between the controls and the cases with regard to the homozygous genotypes however, even if the CC genotype was overrepresented among the AD patients with a border-line p-value (0.054). In addition, when analyzing <italic>UCHL1 </italic>allele A-carrier status (dominant approach) a positive allele A-carrier status was slightly overrepresented in the control group (p = 0.054). The distributions of the <italic>UCHL1 </italic>genotypes were in Hardy-Weinberg equilibrium for the control group (<italic>P </italic>= 0.602 for AA, <italic>P </italic>= 0.692 for AC and <italic>P </italic>= 0.846 for CC) as well as for the AD group (<italic>P </italic>= 0.436 for AA, <italic>P </italic>= 0.647 for AC and <italic>P </italic>= 0.825 for CC).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><italic>UCHL1 </italic>genotype and allele frequencies in patients with AD and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><italic>UCHL1 </italic>genotype<break/>frequencies, n (%)</th><th align="center">AD patients (n = 452)</th><th align="center">Controls (n = 234)</th><th align="center"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left">AA</td><td align="center">15 (3.3)</td><td align="center">6 (2.6)</td><td align="center">0.649</td></tr><tr><td align="left">AC</td><td align="center">112 (24.8)</td><td align="center">77 (32.9)</td><td align="center">0.030</td></tr><tr><td align="left">CC</td><td align="center">325 (71.9)</td><td align="center">151 (64.5)</td><td align="center">0.054</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left"><bold><italic>UCHL1 </italic>allele frequencies, n (%)</bold><sup>&#x02020;</sup></td><td/><td/><td/></tr><tr><td align="left">allele A</td><td align="center">142 (15.7)</td><td align="center">89 (19.0)</td><td align="center">0.128</td></tr><tr><td align="left">allele C</td><td align="center">762 (84.3)</td><td align="center">379 (81.0)</td><td/></tr><tr><td/><td/><td/><td/></tr><tr><td align="left"><bold><italic>UCHL1 </italic>allele A-carrier n (%)</bold></td><td align="center">127 (28.1)</td><td align="center">83 (35.5)</td><td align="center">0.054</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left"><bold><italic>UCHL1 </italic>allele C-carrier n (%)</bold></td><td align="center">437 (96.7)</td><td align="center">228 (97.4)</td><td align="center">0.649</td></tr></tbody></table><table-wrap-foot><p>*Fisher's Exact Test, <sup>&#x02020;</sup>There are two alleles per subject, yielding n = 904 for AD patients and n = 468 for controls. AD = Alzheimer's disease.</p></table-wrap-foot></table-wrap><p>Using a binary logistic regression model including <italic>UCHL1 </italic>allele A and <italic>APOE </italic>&#x003b5;4 allele positivity, age and sex as covariates with AD diagnosis as dependent variable, an adjusted OR of 0.82 ([95% CI 0.55-1.24], <italic>P </italic>= 0.35) was obtained for a positive <italic>UCHL1 </italic>allele A carrier status (table <xref ref-type="table" rid="T3">3</xref>). On the basis of previously reported <italic>UCHL1 </italic>allele frequencies, a standardized difference of 0.29 was calculated [<xref ref-type="bibr" rid="B15">15</xref>]. This yielded a power of the study of 96%, indicating that the lack of association was not spurious. CSF T-tau, P-tau<sub>181 </sub>or A&#x003b2;<sub>1-42 </sub>levels were not affected by the <italic>UCHL1 </italic>S18Y polymorphism (Table <xref ref-type="table" rid="T4">4</xref>). Neither did neuropathological scores of senile plaques and neurofibrillary tangles exhibit any associations with the <italic>UCHL1 </italic>polymorphism (Table <xref ref-type="table" rid="T4">4</xref>). Further, we compared the <italic>UCHL1 </italic>allele A-positivity for AD patients and control subjects respectively between the different centers and found no differences (not shown).</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Binary logistic regression of AD diagnosis versus <italic>UCHL1 </italic>allele A- and <italic>APOE </italic>allele &#x003b5;4-carrier status, age and gender.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable, n = 557</th><th align="center">B</th><th align="center"><bold>S.E</bold>.</th><th align="center">OR</th><th align="center">95%CI</th><th align="center"><italic>P-</italic>value</th></tr></thead><tbody><tr><td align="left">Female gender</td><td align="center">0.29</td><td align="center">0.20</td><td align="center">1.34</td><td align="center">0.90-2.00</td><td align="center">0.147</td></tr><tr><td align="left">Age, years</td><td align="center">0.01</td><td align="center">0.02</td><td align="center">1.01</td><td align="center">0.98-1.04</td><td align="center">0.456</td></tr><tr><td align="left"><italic>UCHL1</italic>, allele A positivity</td><td align="center">-0.20</td><td align="center">0.21</td><td align="center">0.82</td><td align="center">0.55-1.24</td><td align="center">0.348</td></tr><tr><td align="left"><italic>APOE</italic>, allele &#x003b5;4 positivity</td><td align="center">1.96</td><td align="center">0.20</td><td align="center">7.09</td><td align="center">4.83-10.4</td><td align="center">&#x0003c;0.000</td></tr></tbody></table><table-wrap-foot><p>AD = Alzheimer's disease, B = Regression coefficient, S.E. = Standard error, OR = Adjusted odds ratio, CI = Confidence interval</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>CSF biomarkers and neuropathological score in relation to <italic>UCHL1 </italic>allele A-carrier status in AD patients and control subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left" colspan="2"><italic>UCHL1 </italic>allele A-carrier status</th><th/></tr><tr><th align="left">CSF Biomarker</th><th align="left">positive</th><th align="left">negative</th><th align="center"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left">T-tau (pg/ml), Mean &#x000b1; SD</td><td/><td/><td/></tr><tr><td align="left">&#x02003;AD patients</td><td align="left">640 &#x000b1; 368</td><td align="left">613 &#x000b1; 297</td><td align="center">0.790</td></tr><tr><td align="left">&#x02003;Controls</td><td align="left">367 &#x000b1; 175</td><td align="left">381 &#x000b1; 156</td><td align="center">0.528</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">P-tau<sub>181 </sub>(pg/ml), Mean &#x000b1; SD</td><td/><td/><td/></tr><tr><td align="left">&#x02003;AD patients</td><td align="left">80.6 &#x000b1; 35.1</td><td align="left">75.3 &#x000b1; 29.4</td><td align="center">0.434</td></tr><tr><td align="left">&#x02003;Controls</td><td align="left">58.8 &#x000b1; 16.7</td><td align="left">65.7 &#x000b1; 21.1</td><td align="center">0.159</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left">A&#x003b2;<sub>1-42 </sub>(pg/ml), Mean &#x000b1; SD</td><td/><td/><td/></tr><tr><td align="left">&#x02003;AD patients</td><td align="left">406 &#x000b1; 91.5</td><td align="left">410 &#x000b1; 104</td><td align="center">0.996</td></tr><tr><td align="left">&#x02003;Controls</td><td align="left">749 &#x000b1; 195</td><td align="left">703 &#x000b1; 202</td><td align="center">0.246</td></tr><tr><td/><td/><td/><td/></tr><tr><td align="left"><bold>SPs and NFTs score</bold></td><td/><td/><td/></tr><tr><td align="left">Median (25<sup>th </sup>-- 75<sup>th </sup>percentiles)</td><td/><td/><td/></tr><tr><td align="left">&#x02003;AD patients</td><td align="left">7 (5-8)</td><td align="left">7 (6-9)</td><td align="center">0.495</td></tr><tr><td align="left">&#x02003;Controls</td><td align="left">2 (0-3.5)</td><td align="left">0 (0-2)</td><td align="center">0.122</td></tr></tbody></table><table-wrap-foot><p>CSF = cerebrospinal fluid, AD = Alzheimer's disease, SPs = senile plaques, NFTs = neurofibrillary tangles, A&#x003b2; = &#x003b2;-amyloid, *Mann-Whitney U-test</p></table-wrap-foot></table-wrap><p>Aggregation of proteins is a major feature of several neurodegenerative disorders, including Alzheimer's disease (AD). Several lines of evidence suggest that the ubiquitin-proteasome system (UPS) is involved in the pathogenesis of AD [<xref ref-type="bibr" rid="B1">1</xref>]. Accumulation of ubiquitin in senile plaques and neurofibrillary tangles [<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B28">28</xref>], changes in proteasome subunit composition in AD [<xref ref-type="bibr" rid="B29">29</xref>] and an association of AD with polymorphic variants of UBQLN1, encoding for ubiquilin which is a ubiquitin-like protein [<xref ref-type="bibr" rid="B30">30</xref>], are some of the signs pointing towards a role of the UPS in AD. Of special interest is the finding that UCHL1 is oxidized in AD and that it is down-regulated in affected brain areas of AD patients [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. Also interesting is the finding that exogenous UCHL1 ameliorated &#x003b2;-amyloid-induced synaptic and memory dysfunction in an AD mouse model [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>The S18Y polymorphism of the <italic>UCHL1 </italic>gene is associated with lower incidence of Parkinson's disease [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. The mechanism for this protective effect is not known, but it may be at least partially explained by the increased antioxidative capacity demonstrated in neuronal cells expressing the <italic>UCHL1 </italic>S18Y variant [<xref ref-type="bibr" rid="B12">12</xref>]. Little is known about its effect on AD prevalence. A Chinese study has demonstrated lower frequencies of the A allele and the AA genotype in female AD patients as compared to female controls [<xref ref-type="bibr" rid="B19">19</xref>]. However, a genetic study in a Colombian population could not find an association between <italic>UCHL1 </italic>genotypes and AD [<xref ref-type="bibr" rid="B18">18</xref>]. The number of genome-wide association studies in the AD field has increased rapidly; none of these has reported the <italic>UCHL1 </italic>S18Y polymorphism among the significant SNPs found however [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>].</p><p>The allele and genotype frequencies of the <italic>UCHL1 </italic>S18Y polymorphism seen in this study are in accordance with previous results in Swedish populations [<xref ref-type="bibr" rid="B13">13</xref>]. The present study do not support a role of the <italic>UCHL1 </italic>S18Y polymorphism AD however.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MZ participated in the design of the study, analyzed the data statistically and drafted the manuscript. AS performed genetic analyses and helped to draft the manuscript. MvO, MSP and SL performed genetic analyses and revised the manuscript critically. LM, AW and NA collected clinical material and revised the manuscript critically. KB participated in the design of the study and revised the manuscript critically. HZ conceived of the study, helped in analyzing the data and helped in drafting the manuscript.</p><p>All authors have read and approved the final manuscript.</p></sec></body><back><sec><title>Acknowledgements</title><p>This work was supported by grants from the Swedish Research Council, the Royal Swedish Academy of Sciences, the Sahlgrenska University Hospital, the G&#x000f6;teborg Medical Society, Swedish Brain Power, Hjalmar Svenssons forskningsfond, Stiftelsen f&#x000f6;r Gamla Tj&#x000e4;narinnor and Alzheimerfonden.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Oddo</surname><given-names>S</given-names></name><article-title>The ubiquitin-proteasome system in Alzheimer's disease</article-title><source>J Cell Mol Med</source><year>2008</year><volume>12</volume><fpage>363</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2008.00276.x</pub-id><pub-id pub-id-type="pmid">18266959</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Petroski</surname><given-names>MD</given-names></name><article-title>The ubiquitin system, disease, and drug discovery</article-title><source>BMC Biochem</source><year>2008</year><volume>9</volume><issue>Suppl 1</issue><fpage>S7</fpage><pub-id pub-id-type="doi">10.1186/1471-2091-9-S1-S7</pub-id><pub-id pub-id-type="pmid">19007437</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Tai</surname><given-names>HC</given-names></name><name><surname>Schuman</surname><given-names>EM</given-names></name><article-title>Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction</article-title><source>Nat Rev Neurosci</source><year>2008</year><volume>9</volume><fpage>826</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1038/nrn2499</pub-id><pub-id pub-id-type="pmid">18931696</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Dhillon</surname><given-names>AP</given-names></name><name><surname>Rode</surname><given-names>J</given-names></name><name><surname>Dhillon</surname><given-names>DP</given-names></name><name><surname>Moss</surname><given-names>E</given-names></name><name><surname>Thompson</surname><given-names>RJ</given-names></name><name><surname>Spiro</surname><given-names>SG</given-names></name><name><surname>Corrin</surname><given-names>B</given-names></name><article-title>Neural markers in carcinoma of the lung</article-title><source>Br J Cancer</source><year>1985</year><volume>51</volume><fpage>645</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">2986665</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Otsuki</surname><given-names>T</given-names></name><name><surname>Yata</surname><given-names>K</given-names></name><name><surname>Takata-Tomokuni</surname><given-names>A</given-names></name><name><surname>Hyodoh</surname><given-names>F</given-names></name><name><surname>Miura</surname><given-names>Y</given-names></name><name><surname>Sakaguchi</surname><given-names>H</given-names></name><name><surname>Hatayama</surname><given-names>T</given-names></name><name><surname>Hatada</surname><given-names>S</given-names></name><name><surname>Tsujioka</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Murakami</surname><given-names>H</given-names></name><name><surname>Sadahira</surname><given-names>Y</given-names></name><name><surname>Sugihara</surname><given-names>T</given-names></name><article-title>Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells</article-title><source>Br J Haematol</source><year>2004</year><volume>127</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2004.05205.x</pub-id><pub-id pub-id-type="pmid">15491288</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>RJ</given-names></name><name><surname>Doran</surname><given-names>JF</given-names></name><name><surname>Jackson</surname><given-names>P</given-names></name><name><surname>Dhillon</surname><given-names>AP</given-names></name><name><surname>Rode</surname><given-names>J</given-names></name><article-title>PGP 9.5--a new marker for vertebrate neurons and neuroendocrine cells</article-title><source>Brain Res</source><year>1983</year><volume>278</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(83)90241-X</pub-id><pub-id pub-id-type="pmid">6640310</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Healy</surname><given-names>DG</given-names></name><name><surname>Abou-Sleiman</surname><given-names>PM</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><article-title>Genetic causes of Parkinson's disease: UCHL-1</article-title><source>Cell Tissue Res</source><year>2004</year><volume>318</volume><fpage>189</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1007/s00441-004-0917-3</pub-id><pub-id pub-id-type="pmid">15221445</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Osaka</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Takizawa</surname><given-names>S</given-names></name><name><surname>Setsuie</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Nishikawa</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>YJ</given-names></name><name><surname>Sakurai</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>T</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name><name><surname>Chiba</surname><given-names>S</given-names></name><name><surname>Namikawa</surname><given-names>K</given-names></name><name><surname>Kiyama</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>S</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><article-title>Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>1945</fpage><lpage>1958</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddg211</pub-id><pub-id pub-id-type="pmid">12913066</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Leroy</surname><given-names>E</given-names></name><name><surname>Boyer</surname><given-names>R</given-names></name><name><surname>Auburger</surname><given-names>G</given-names></name><name><surname>Leube</surname><given-names>B</given-names></name><name><surname>Ulm</surname><given-names>G</given-names></name><name><surname>Mezey</surname><given-names>E</given-names></name><name><surname>Harta</surname><given-names>G</given-names></name><name><surname>Brownstein</surname><given-names>MJ</given-names></name><name><surname>Jonnalagada</surname><given-names>S</given-names></name><name><surname>Chernova</surname><given-names>T</given-names></name><name><surname>Dehejia</surname><given-names>A</given-names></name><name><surname>Lavedan</surname><given-names>C</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Steinbach</surname><given-names>PJ</given-names></name><name><surname>Wilkinson</surname><given-names>KD</given-names></name><name><surname>Polymeropoulos</surname><given-names>MH</given-names></name><article-title>The ubiquitin pathway in Parkinson's disease</article-title><source>Nature</source><year>1998</year><volume>395</volume><fpage>451</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1038/26652</pub-id><pub-id pub-id-type="pmid">9774100</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Setsuie</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>K</given-names></name><article-title>The functions of UCH-L1 and its relation to neurodegenerative diseases</article-title><source>Neurochem Int</source><year>2007</year><volume>51</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2007.05.007</pub-id><pub-id pub-id-type="pmid">17586089</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Fallon</surname><given-names>L</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Lansbury</surname><given-names>PT</given-names><suffix>Jr</suffix></name><article-title>The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility</article-title><source>Cell</source><year>2002</year><volume>111</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)01012-7</pub-id><pub-id pub-id-type="pmid">12408865</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Kyratzi</surname><given-names>E</given-names></name><name><surname>Pavlaki</surname><given-names>M</given-names></name><name><surname>Stefanis</surname><given-names>L</given-names></name><article-title>The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells</article-title><source>Hum Mol Genet</source><year>2008</year><volume>17</volume><fpage>2160</fpage><lpage>2171</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddn115</pub-id><pub-id pub-id-type="pmid">18411255</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Carmine Belin</surname><given-names>A</given-names></name><name><surname>Westerlund</surname><given-names>M</given-names></name><name><surname>Bergman</surname><given-names>O</given-names></name><name><surname>Nissbrandt</surname><given-names>H</given-names></name><name><surname>Lind</surname><given-names>C</given-names></name><name><surname>Sydow</surname><given-names>O</given-names></name><name><surname>Galter</surname><given-names>D</given-names></name><article-title>S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden</article-title><source>Parkinsonism Relat Disord</source><year>2007</year><volume>13</volume><fpage>295</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2006.12.002</pub-id><pub-id pub-id-type="pmid">17287139</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Elbaz</surname><given-names>A</given-names></name><name><surname>Levecque</surname><given-names>C</given-names></name><name><surname>Clavel</surname><given-names>J</given-names></name><name><surname>Vidal</surname><given-names>JS</given-names></name><name><surname>Richard</surname><given-names>F</given-names></name><name><surname>Correze</surname><given-names>JR</given-names></name><name><surname>Delemotte</surname><given-names>B</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Alperovitch</surname><given-names>A</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><article-title>S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship</article-title><source>Mov Disord</source><year>2003</year><volume>18</volume><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1002/mds.10326</pub-id><pub-id pub-id-type="pmid">12539205</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Lincoln</surname><given-names>SJ</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name><article-title>Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>1858</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">10563640</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Elbaz</surname><given-names>A</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Mellick</surname><given-names>GD</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name><name><surname>Satoh</surname><given-names>J</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name><article-title>UCHL1 is a Parkinson's disease susceptibility gene</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1002/ana.20017</pub-id><pub-id pub-id-type="pmid">15048890</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Hutter</surname><given-names>CM</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Nutt</surname><given-names>JG</given-names></name><name><surname>Higgins</surname><given-names>DS</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>JW</given-names></name><name><surname>Leis</surname><given-names>BC</given-names></name><name><surname>Montimurro</surname><given-names>JS</given-names></name><name><surname>Kay</surname><given-names>DM</given-names></name><name><surname>Edwards</surname><given-names>KL</given-names></name><name><surname>Payami</surname><given-names>H</given-names></name><name><surname>Zabetian</surname><given-names>CP</given-names></name><article-title>Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease</article-title><source>Eur J Neurol</source><year>2008</year><volume>15</volume><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">18093156</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Forero</surname><given-names>DA</given-names></name><name><surname>Benitez</surname><given-names>B</given-names></name><name><surname>Arboleda</surname><given-names>G</given-names></name><name><surname>Yunis</surname><given-names>JJ</given-names></name><name><surname>Pardo</surname><given-names>R</given-names></name><name><surname>Arboleda</surname><given-names>H</given-names></name><article-title>Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia</article-title><source>Neurosci Res</source><year>2006</year><volume>55</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2006.04.006</pub-id><pub-id pub-id-type="pmid">16698101</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>S</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><article-title>Genetic association between Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population</article-title><source>Brain Res</source><year>2006</year><volume>1087</volume><fpage>28</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2006.02.121</pub-id><pub-id pub-id-type="pmid">16626667</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Andersson</surname><given-names>ME</given-names></name><name><surname>Sjolander</surname><given-names>A</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Jern</surname><given-names>C</given-names></name><name><surname>Jood</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease</article-title><source>Int J Mol Med</source><year>2007</year><volume>20</volume><fpage>233</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">17611642</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Zetterberg</surname><given-names>M</given-names></name><name><surname>Landgren</surname><given-names>S</given-names></name><name><surname>Andersson</surname><given-names>ME</given-names></name><name><surname>Palmer</surname><given-names>MS</given-names></name><name><surname>Gustafson</surname><given-names>DR</given-names></name><name><surname>Skoog</surname><given-names>I</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Thelle</surname><given-names>DS</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><article-title>Association of complement factor H Y402H gene polymorphism with Alzheimer's disease</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2007</year><volume>147B</volume><issue>6</issue><fpage>720</fpage><lpage>6</lpage></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Price</surname><given-names>D</given-names></name><name><surname>Stadlan</surname><given-names>EM</given-names></name><article-title>Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease</article-title><source>Neurology</source><year>1984</year><volume>34</volume><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Ricksten</surname><given-names>A</given-names></name><name><surname>Prince</surname><given-names>JA</given-names></name><name><surname>Brookes</surname><given-names>AJ</given-names></name><name><surname>Emahazion</surname><given-names>T</given-names></name><name><surname>Wasslavik</surname><given-names>C</given-names></name><name><surname>Bogdanovic</surname><given-names>N</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><name><surname>Batsman</surname><given-names>S</given-names></name><name><surname>Marcusson</surname><given-names>J</given-names></name><name><surname>Nagga</surname><given-names>K</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Regland</surname><given-names>B</given-names></name><name><surname>Olofsson</surname><given-names>H</given-names></name><name><surname>Hesse</surname><given-names>C</given-names></name><name><surname>Davidsson</surname><given-names>P</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Jansson</surname><given-names>A</given-names></name><name><surname>Palmqvist</surname><given-names>L</given-names></name><name><surname>Rymo</surname><given-names>L</given-names></name><article-title>No association between the alpha2-macroglobulin (A2 M) deletion and Alzheimer's disease, and no change in A2 M mRNA, protein, or protein expression</article-title><source>J Neural Transm</source><year>2000</year><volume>107</volume><fpage>1065</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1007/s007020070052</pub-id><pub-id pub-id-type="pmid">11041282</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Prince</surname><given-names>JA</given-names></name><name><surname>Feuk</surname><given-names>L</given-names></name><name><surname>Howell</surname><given-names>WM</given-names></name><name><surname>Jobs</surname><given-names>M</given-names></name><name><surname>Emahazion</surname><given-names>T</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Brookes</surname><given-names>AJ</given-names></name><article-title>Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation</article-title><source>Genome Res</source><year>2001</year><volume>11</volume><fpage>152</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1101/gr.150201</pub-id><pub-id pub-id-type="pmid">11156624</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Ii</surname><given-names>K</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Hirano</surname><given-names>A</given-names></name><article-title>Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly</article-title><source>J Neuropathol Exp Neurol</source><year>1997</year><volume>56</volume><fpage>125</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1097/00005072-199702000-00002</pub-id><pub-id pub-id-type="pmid">9034365</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Ihara</surname><given-names>Y</given-names></name><article-title>Ubiquitin is a component of paired helical filaments in Alzheimer's disease</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>1641</fpage><lpage>1644</lpage><pub-id pub-id-type="doi">10.1126/science.3029875</pub-id><pub-id pub-id-type="pmid">3029875</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Friedman</surname><given-names>R</given-names></name><name><surname>Shaw</surname><given-names>G</given-names></name><name><surname>Chau</surname><given-names>V</given-names></name><article-title>Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains</article-title><source>Proc Natl Acad Sci USA</source><year>1987</year><volume>84</volume><fpage>3033</fpage><lpage>3036</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.9.3033</pub-id><pub-id pub-id-type="pmid">3033674</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Tabaton</surname><given-names>M</given-names></name><name><surname>Cammarata</surname><given-names>S</given-names></name><name><surname>Mancardi</surname><given-names>G</given-names></name><name><surname>Manetto</surname><given-names>V</given-names></name><name><surname>Autilio-Gambetti</surname><given-names>L</given-names></name><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Gambetti</surname><given-names>P</given-names></name><article-title>Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles</article-title><source>Proc Natl Acad Sci USA</source><year>1991</year><volume>88</volume><fpage>2098</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.6.2098</pub-id><pub-id pub-id-type="pmid">1706517</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Mishto</surname><given-names>M</given-names></name><name><surname>Bellavista</surname><given-names>E</given-names></name><name><surname>Santoro</surname><given-names>A</given-names></name><name><surname>Stolzing</surname><given-names>A</given-names></name><name><surname>Ligorio</surname><given-names>C</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Spazzafumo</surname><given-names>L</given-names></name><name><surname>Chiappelli</surname><given-names>M</given-names></name><name><surname>Licastro</surname><given-names>F</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Pession</surname><given-names>A</given-names></name><name><surname>Ohm</surname><given-names>T</given-names></name><name><surname>Grune</surname><given-names>T</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><article-title>Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains</article-title><source>Neurobiol Aging</source><year>2006</year><volume>27</volume><fpage>54</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.12.004</pub-id><pub-id pub-id-type="pmid">16298241</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Parkinson</surname><given-names>M</given-names></name><name><surname>Ingelsson</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Ramasamy</surname><given-names>K</given-names></name><name><surname>Mullin</surname><given-names>K</given-names></name><name><surname>Menon</surname><given-names>R</given-names></name><name><surname>Sampson</surname><given-names>AJ</given-names></name><name><surname>Hsiao</surname><given-names>MY</given-names></name><name><surname>Elliott</surname><given-names>KJ</given-names></name><name><surname>Velicelebi</surname><given-names>G</given-names></name><name><surname>Moscarillo</surname><given-names>T</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Wagner</surname><given-names>SL</given-names></name><name><surname>Becker</surname><given-names>KD</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Tanzi</surname><given-names>RE</given-names></name><article-title>Family-based association between Alzheimer's disease and variants in UBQLN1</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>884</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa042765</pub-id><pub-id pub-id-type="pmid">15745979</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Castegna</surname><given-names>A</given-names></name><name><surname>Aksenov</surname><given-names>M</given-names></name><name><surname>Aksenova</surname><given-names>M</given-names></name><name><surname>Thongboonkerd</surname><given-names>V</given-names></name><name><surname>Klein</surname><given-names>JB</given-names></name><name><surname>Pierce</surname><given-names>WM</given-names></name><name><surname>Booze</surname><given-names>R</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name><name><surname>Butterfield</surname><given-names>DA</given-names></name><article-title>Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1</article-title><source>Free Radic Biol Med</source><year>2002</year><volume>33</volume><fpage>562</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(02)00914-0</pub-id><pub-id pub-id-type="pmid">12160938</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Pasinetti</surname><given-names>GM</given-names></name><article-title>Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia</article-title><source>J Neurosci Res</source><year>2001</year><volume>65</volume><fpage>471</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1002/jnr.1176</pub-id><pub-id pub-id-type="pmid">11550214</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Gong</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Vitolo</surname><given-names>OV</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Staniszewski</surname><given-names>A</given-names></name><name><surname>Moolman</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Shelanski</surname><given-names>M</given-names></name><name><surname>Arancio</surname><given-names>O</given-names></name><article-title>Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>775</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.046</pub-id><pub-id pub-id-type="pmid">16923396</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Beecham</surname><given-names>GW</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Slifer</surname><given-names>MA</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><article-title>Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease</article-title><source>Am J Hum Genet</source><year>2009</year><volume>84</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2008.12.008</pub-id><pub-id pub-id-type="pmid">19118814</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>R</given-names></name><name><surname>Hollingworth</surname><given-names>P</given-names></name><name><surname>Sims</surname><given-names>R</given-names></name><name><surname>Gerrish</surname><given-names>A</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Pahwa</surname><given-names>JS</given-names></name><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Dowzell</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Stretton</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>AR</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Powell</surname><given-names>J</given-names></name><name><surname>Proitsi</surname><given-names>P</given-names></name><name><surname>Lupton</surname><given-names>MK</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Rubinsztein</surname><given-names>DC</given-names></name><name><surname>Gill</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>B</given-names></name><name><surname>Lynch</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>KS</given-names></name><name><surname>Passmore</surname><given-names>PA</given-names></name><name><surname>Craig</surname><given-names>D</given-names></name><name><surname>McGuinness</surname><given-names>B</given-names></name><name><surname>Todd</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>C</given-names></name><article-title>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1038/ng.440</pub-id><pub-id pub-id-type="pmid">19734902</pub-id></mixed-citation></ref></ref-list></back></article>